Rigrodsky & Long, P.A.:
& Long, P.A. announces that it is investigating potential legal
claims against the board of directors of Idenix Pharmaceuticals, Inc.
("Idenix" or the "Company") (NASDAQ GS: IDIX)
regarding possible breaches of fiduciary duties and other violations of
law related to the Company's entry into an agreement to be acquired by
Merck & Co., Inc. ("Merck") (NYSE: MRK),
in a transaction valued at approximately $3.85 billion.
Click here to learn more: http://www.rigrodskylong.com/investigations/idenix-pharmaceuticals-inc-idix.
Under the terms of the agreement, public shareholders of Idenix would
receive $24.50 in cash for each share of Idenix they own.
The investigation concerns whether Idenix's board of directors failed to
adequately shop the Company and obtain the best possible value for
Idenix's shareholders before entering into an agreement with Merck.
If you own the common stock of Idenix and purchased your shares before
June 9, 2014, if you have information or would like to learn more about
these claims, or if you wish to discuss these matters or have any
questions concerning this announcement or your rights or interests with
respect to these matters, please contact Seth D. Rigrodsky or Gina M.
Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120,
Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail to email@example.com,
or at: http://www.rigrodskylong.com/investigations/idenix-pharmaceuticals-inc-idix.
& Long, P.A., with offices in Wilmington, Delaware and Garden
City, New York, regularly prosecutes securities
class, derivative and direct actions, shareholder rights litigation and
corporate governance litigation, on behalf of shareholders in states
and federal courts throughout the United States.
Attorney advertising. Prior results do not guarantee a similar outcome.
[ Back To NFVZone's Homepage ]